Micro Aftermath Archived

Hims & Hers Health, Inc. analysis

Activity declining — narrative losing relevance.

Score 0.3

Velocity ▲ 0.0

Articles 9

Sources 3

Sentiment Timeline

Event Timeline

Jul 07, 2026 Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a … Neutral

Jun 25, 2026 Is Hims & Hers Health, Inc. (HIMS) a Top Weight Loss Stock … Bullish

Jun 17, 2026 Hims & Hers (HIMS) Climbs 12.5% as Obesity Market Momentum Builds Bullish

Jun 07, 2026 Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy … Neutral

Jun 05, 2026 Great News: Wall Street Is Turning Bullish on This Troubled Telehealth Stock Bullish

May 12, 2026 Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance Bearish

May 10, 2026 GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue Bullish

May 03, 2026 Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy … Neutral

Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance CNBC · May 12, 2026 Mixed Hims & Hers stock sinks after quarterly loss, sales miss Yahoo Finance · May 12, 2026 Mixed GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue Nasdaq · May 10, 2026 Mixed

🤖 AI Overview

Hims & Hers Health, Inc. (HIMS) stock experienced a significant downturn in early April, plummeting 15% in premarket trading following the company's first-quarter earnings report. The telehealth company posted a net loss of $92 million, more than doubling the loss from the same period last year, and missed Wall Street's sales expectations. This performance was attributed to higher costs stemming from the company's pivot towards branded weight-loss medications.

The market impact of Hims & Hers' poor performance was immediate and severe. The company's stock price, which had been volatile in recent months, dropped sharply, wiping out gains made earlier in the year. The telehealth sector as a whole may face increased scrutiny, as investors reassess the financial viability of companies in this space. Competitors like GoodRx, which has experienced relatively flat revenue growth, may benefit from a shift in investor sentiment away from higher-risk telehealth companies.

Investors should closely monitor Hims & Hers' upcoming earnings releases, scheduled for August 11, 2023, and any updates on the company's weight-loss medication pipeline. Additionally, the broader telehealth sector's performance and any regulatory changes that may impact the industry will be crucial factors in determining the future trajectory of Hims & Hers' stock price.

AI Overview as of Jun 21, 2026

Timeline

Last UpdatedMay 03, 2026

Hims & Hers Health, Inc. analysis

Sentiment Timeline

Event Timeline

Related Articles